MAXONA Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to proceed with a Phase 2 clinical trial of its lead drug candidate, MAX-001.

• Compound Details: MAX-001 is a proprietary optimised extended-release oral formulation of nefopam, being developed as a non-opioid, non-NSAID therapy for acute and chronic pain.
• Clinical Study: The FDA clearance allows the company to proceed with the randomised, controlled Phase 2 trial (MAX-001-201) in the United States to evaluate the efficacy and safety of MAX-001 for acute pain.
• Safety History: The clearance follows a completed Phase 1 clinical trial that demonstrated dose-proportional pharmacokinetics and reported no serious adverse events.
• Therapeutic Positioning: MAX-001 is designed to provide rapid-onset and extended-duration analgesia as a potential alternative to opioid and NSAID-based pain treatments.

This summary is based on a news report published by BioSpectrum Asia.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.